Prot #MORAb-202-G000-201: A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a Folate Receptor Alpha (FRα)-Targeting Antibody-Drug Conjugate (ADC) in Subjects With Selected Tumor Types

Project: Research project

Project Details

StatusActive
Effective start/end date2/3/222/3/25

Funding

  • PPD Investigator Services, LLC (Prot #MORAb-202-G000-201)
  • Eisai, Inc. (Prot #MORAb-202-G000-201)